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Abstract
Objective: To evaluate the use of paracetamol in the treatment of closure of patent ductus arteriosus
(PDA), as well as to investigate the amount of adverse side effects. Design: Systematic literature review.
Methods: Searches were done in PubMed and Google scholar, using the search terms Paracetamol for
patent ductus arteriosus and alternative treatment patent ductus arteriosus. In PubMed the following
limits and terms were used: randomized control trial, English, and secondary endpoints. Results:
Randomized control trial studies by Dash et al., El-Mashad et al., and El-Farrash et al. were included
based on inclusion/exclusion criteria of the meta-analysis and with secondary endpoints including
adverse side effects. Conclusion: Paracetamol has been found to be as efficacious, however not
superior, in the closure of PDA when compared to the use of non-steroidal anti-inflammatories such as
indomethacin and ibuprofen.
Introduction
Patent ductus arteriosus (PDA) is a congenital heart disorder that is characterized by the
persistent patency of a neonate’s ductus arteriosus (DA) after birth.1 In utero, the ductus arteriosus
serves as a communication between the aorta and pulmonary artery, allowing for fetal blood to bypass
the lungs. This is a normal finding as it is a blood vessel that allows for the fetal blood to bypass the
lungs in utero.2 However, during the transition period of a neonates life there are major steps that occur
to ensure that the baby is well adapted to the extrauterine world. A decrease in peripheral vascular (PV)
resistance allows blood to flow into the lungs, followed by expansion of the lungs and closure of the
ductus arteriosus.3 In the case of a neonate with PDA, these steps do not occur. Ultimately, “this causes
an impaired transmission of blood among the pulmonary artery and aorta.”1 PDA is a serious
complication, and if left untreated, it can lead to hypoxia, respiratory distress, and/or congestive heart
failure.
The mechanism of ductus arteriosus patency in utero is accomplished by the continuous
production of prostaglandin E2 by both the ductus and placenta, causing dilation of the vessels and
patency of the ductus arteriosus. The patency results in a left to right shunt of blood from the aorta into
the pulmonary artery, subsequently causing increased pulmonary blood flow and preload. Patients with
this condition present in a variety of ways, from feeling fatigued and diaphoretic to increasing dyspnea
and cardiovascular problems.1
Treatment of patent ductus arteriosus focuses on inhibiting prostaglandins, due to their
important role in maintaining patency in utero. In patients with this condition, one of two treatment
options exist. Initially, NSAIDs, like ibuprofen and indomethacin are administered to cause constriction
of the DA, leading to closure.1 NSAIDS accomplish this via inhibition of the COX (cyclooxygenase-2)
enzyme, thus preventing the production of prostaglandins.1 The use of NSAIDS can cause weakened
platelet aggregation, hyperbilirubinemia, peripheral vasoconstriction and decreased organ blood flow
leading to renal dysfunction and GI perforation.4 In the case that the medications fail, surgery is
considered for the patients.1
NSAIDS have many contraindications to their use. For example, the use of these medications are
forbidden in conditions such as renal failure, intracerebral hemorrhage, gastrointestinal problems and
thrombocytopenia. ⁴ In neonates with these conditions, surgery would be the only option for treatment.

Surgery is an invasive option for treatment and may have more severe complications. It is imperative to
have other pharmaceutical agents that are able to be used for this condition.
The use of paracetamol as an alternative drug for the treatment of PDA closure has gained
attention recently and is an exciting advancement. Much like NSAIDS, paracetamol inhibits
prostaglandin synthesis, however, it has an advantage in that it has no added peripheral vasoconstrictive
effect. 4
The goal of this study is to evaluate the use of paracetamol in the treatment of closure of PDA,
as well as to investigate the adverse side effects that are typically coupled with the use of NSAIDs like
indomethacin and/or ibuprofen.
Methods
PubMed was the primary database used to search for randomized control trial studies. Search
terms included “paracetamol for patent ductus arteriosus” and “alternative treatment patent ductus
arteriosus. Other records were identified using Google scholar, including the search terms “paracetamol
as treatment for patent ductus arteriosus.” Upon isolating articles intended for use in the meta-analysis,
many were excluded for a variety of reasons. These included a large degree of age variation, inadequate
sample size, multiple interventions for
closure of PDA, the primary endpoint
not being related to ductus closure.
More information regarding search
strategy can be found in Figure 1.
Quality assessment criteria included
studies with a primary endpoint of
efficacy of PDA closure with use of
paracetamol compared with other
prostaglandin inhibitors. Secondary
endpoints that measured the
prevalence of adverse effects
associated with both the use of
paracetamol and other prostaglandin
inhibitors were important to be
included in the study. A total of 20
articles were found through the
database searches. 17 of those articles
were excluded for various reasons.
However, the major reason for
exclusion was the lack of a primary
endpoint including closure of the PDA.
Others were excluded due to neonatal
age not preterm, small sample size,
and lack of comparison of paracetamol
Figure 1: PRISMA Flow Diagram including search
to an NSAID (i.e. indomethacin, or
criteria, listed terms, and reasons for exclusions.

ibuprofen). Thus, this analysis includes 3 of the 20 identified papers.
Results:
El- Mashad et al. 4
Three hundred neonates with hemodynamically significant PDA (hs-PDA) were admitted into
this randomized control study. 4 Inclusion criteria included weight <1500 grams or gestational age <28
weeks in the first 2 weeks of life, coupled with a hs-PDA diagnosed with echocardiography.4 Exclusion
criteria included patients with any of the following: Major congenital anomalies, sepsis, NEC (Necrotizing
Enterocolitis), IVH (Intraventricular hemorrhage), urine output <1ml/kg/hr in last 24 hours, elevated
creatinine concentration >1.5, platelet count <100,000/mL, complex congenital heart, or ductal
dependent lesions.4 See Table 1 for a breakdown of inclusion and exclusion criteria. These patients were
randomized into three groups; one being infused with paracetamol, one with ibuprofen and the last
with indomethacin. See Figure 2 for flow chart of administration details. Initially, there were no
differences in secondary outcomes regarding serum creatinine, BUN (blood urea nitrogen), bilirubin,
SGPT (Alanine Aminotransferase), SGOT (Aspartate Aminotransferase), platelet count, Hgb (hemoglobin)
and Uop (urinary output). Upon completion of the study, there was found to be no significant difference
in the rate and efficacy of PDA closure within the three groups. With primary treatment, there was
found to be an 80% closure rate with the use of paracetamol, 77% closure with the use of ibuprofen and
81% closure rate with the use of indomethacin. After completing the second treatment, the closure
rates increased to 88% for paracetamol, 83% for ibuprofen and 87% for indomethacin.4 An increase in GI
bleeds was the only statistically significant adverse outcome and was seen with the use of both
ibuprofen and indomethacin. However, there was found to be an increase in serum creatinine levels
and serum BUN in both the ibuprofen and indomethacin groups.4 There was also found to be a
reduction in platelet count and urine output in these groups. However, patients infused with ibuprofen
proved to be the only group that possessed a moderate elevation in bilirubin. Interestingly however,
within all three groups there was found to be no significant difference in hemoglobin or liver enzymes. 4
The study was completed without complication. It worked to record a primary endpoint of
efficacy as well as secondary endpoints of adverse effects associated with each treatment regimen. The
information presented was thought to be statistically significant as the results were based off a type 1
error of 0.05 and a statistical power of 90%. See Table 2 for statistical analysis. This means that the null
hypothesis can be rejected, and results are able to be adequately considered, as they are statistically
significant.
There were some limitations within this study, however. The study was not thought to be fully
blinded due to the differing administration techniques and timing of doses, yet still possessed some
aspects of anonymity as the individuals assessing the results were completely blinded to the treatment
groups. The authors also explained that there was a younger gestational age used in patients treated
with the ibuprofen group. This was not found to be statistically significant.

El-Farrash et al. 5
A double-blind randomized control trial with 60 preterm infants divided into two groups: 30
infants receiving oral ibuprofen and 30 receiving oral paracetamol. Inclusion criteria used included

gestational age <34 weeks, postnatal age of 2-7 days, and color doppler echocardiographic evidence of a
hemodynamically significant PDA (hs-PDA). Exclusion criteria included patients with any of the following,
bleeding tendency, platelet count <60,000/mm3, urine output less than 1ml/kg/hr, creatinine
concentration >1.8 mg/dL, congenital heart disease, or other major congenital abnormalities.5 See Table
1 for a breakdown of inclusion and exclusion criteria. The infants were given a second course of the
same treatment if the primary closure was not obtained. See Figure 2 for flow chart of administration
details. The study compared quantitative parametric variables using t-test while using analysis of
variance (ANOVA) with post hoc test for comparison between more than two groups. Chi-square or
Fisher exact test was used for the comparison of qualitative data. Data was analyzed using intention to
treat principle. The authors concluded that oral paracetamol was similar in efficacy as ibuprofen in
closure of the PDA with one course of administration. Ductal closure was reported in 24 of 30 in the oral
ibuprofen group, and 28 out of 30 in the oral paracetamol group with no significant differences in lab
values or side effects.5 See Table 3 for visual breakdown of results.
Paracetamol was found to be superior to ibuprofen in infants with a significant decrease in end
diastolic flow velocity in the left pulmonary artery, a decreased right ventricular systolic pressure, and a
decreased left atrium aortic root ratio. See Table 4 for statistical breakdown of echocardiographic
findings. When comparing the mean differences between pre and post treatment PDA size of with the
use of paracetamol and ibuprofen after second course of treatment, paracetamol was found to be
superior. Oral paracetamol was found to be similar in safety profile in terms of GI perforation or
bleeding, necrotizing enterocolitis, bronchopulmonary dysfunction, interventricular hemorrhage,
thrombocytopenia, hepatic or renal dysfunction.5
Limitations of the study included not having a placebo group, which could have helped estimate
the spontaneous PDA closure rate.5 However, the authors deemed it unethical to have a placebo group
for treatment of a hs-PDA due to intentional lack of treatment for the infant. The results were
statistically significant with a p-value consistently <0.05. The results of this study show that paracetamol
is an effective and safe treatment for PDA that may be used first line.

Dash et al.6
Seventy-seven neonates with hs-PDA were admitted to the randomized control study. Inclusion
criteria listed included weight <1500 grams and echocardiography proven of hs-PDA >1.5mm with a left
to right shunt ratio of the left atrium to the aorta >1.5:1 within the first 48 hours.6 Exclusion criteria
included patients with any of the following: major congenital anomalies, sepsis, platelet count
<50,000/mL, complex congenital heart, ductal dependent lesions, inability to administer the drug within
48 hours of birth, polycystic disease of kidney or multicystic kidney, maternal tocolytic therapy with
prostaglandin inhibitors, hydrops fetalis, or urine output less than 1mL/kg/hr.6 See Table 1 for inclusion
and exclusion criteria. The neonates were randomized into two groups and administered 1 of 2
treatment options: enteral administration of paracetamol or intravenous indomethacin. 38 neonates
were given parenteral paracetamol, while 39 neonates were given IV indomethacin. See Figure 2 for
dosage breakdown. Both treatments were found to be efficacious in the closure of PDA, with
paracetamol having an 100% closure rate and indomethacin possessing a 94.6% closure rate. They also
found that use of either medication did not increase the incidence of secondary endpoints. See Table 3

for comparison of drug closures and secondary endpoints. Additionally, there was also found to be no
hepatotoxicity associated with administration of either. 6
The administration of medication was not via the same route and thus could produce some
discrepancies. Also, the study only worked to compare indomethacin and paracetamol and not the use
of ibuprofen. Interestingly however, the validity of the study can be questioned as they used per
protocol analysis in comparison to the recommended intention to treat. The study was adequate in
sample size and number of studies used. Authors adequately depicted their search strategies and
methods through the incorporation of the Prisma. Overall, this study demonstrated statistically
significant results and may be used to discuss Paracetamol as an option for PDA closure versus
indomethacin.
Discussion:
PDA is a condition seen in premature infants that can lead to a plethora of serious health
conditions. Currently, there are two main options for closure of the PDA; pharmacologic treatment or
surgery. Pharmacologic treatment is thought to be first line due to its safety, efficacy, and limited
invasiveness.4 Cyclooxygenase inhibitors such as indomethacin and ibuprofen have traditionally been
used to manage this condition. Paracetamol has provided a recent alternative approach with its work via
the inhibition of prostaglandin synthesis in the CNS.3 Recent studies have assessed the efficacy of this
novel treatment in comparison to the first line medications. However, studies have been limited in
producing a side-by-side comparison of the side effects of each of the treatments. The goal of this metaanalysis was to assess both the efficacy and safety profile of the use of paracetamol.
The pathophysiology behind NSAIDs versus Paracetamol for treatment of PDA is important in
understanding why adverse side effects occur. Inhibiting prostaglandins systemically causes
vasoconstriction and causes closure of PDA as a result. There are more systemic and widespread effects
associated with certain medications such as ibuprofen and indomethacin due to the non-selective
nature of these medications. Both COX 1&2 enzymes are beneficial to the body in a variety of ways.
COX enzymes cause the production of prostaglandins, thus inhibiting them can help us with the closure
of PDA. However, COX 1 and 2 have effects on the GI tract as well as the kidney. They are thought to be
protective in both organ systems. In the GI tract, they cause an increase in mucus production and
bicarbonate as well as increased blood flow. In the kidneys, COX causes afferent arteriole vasodilation
and increased sodium and water excretion. In the cardiovascular system, it can cause vasodilation and
inhibition of platelets, while on the other hand causing platelet aggregation and vasoconstriction. Thus,
inhibiting these are most likely to close the PDA but also cause mucosal injury in the form of GI bleeds,
as well as hypertension and kidney failure.
The use of these medications is commonly associated with hepatic failure, renal impairment,
and platelet inhibitions. However, Paracetamol is not an NSAID and does not provide inhibition of
platelets. Although the mechanism of action is unclear, it is known to work by inhibiting prostaglandin
synthesis in the CNS.3 The most serious adverse effect associated with Tylenol is hepatotoxicity, but is
only associated with doses as high as 15g/day. Treatment of PDA uses very low doses of Paracetamol, so
hepatotoxicity is not a complication. The referred studies have also worked to elicit whether the use of
Paracetamol is a safer treatment option.

Initially, it was thought that each medication has a similar efficacy due to the mechanism of
action being the inhibition of prostaglandins. However, the ways in which these medications work is
different, leading to the varying adverse effects seen with each. Thus, the increase of adverse effects
was suspected to be found with the use of the traditional NSAID treatment and much less so with the
use of paracetamol.
Each of the trials reviewed in this meta-analysis depicted that paracetamol has similar efficacy in
PDA closure as the use of traditional cox inhibitors, such as indomethacin and ibuprofen. In the trials
produced by El-Mashad et al., a closure rate of 80% was found with paracetamol, 77% for ibuprofen and
81% for indomethacin.4 El Farrash et al., found that the use of oral paracetamol and oral ibuprofen were
also similar in efficacy. They did note however, that paracetamol was actually found to be superior to
ibuprofen in infants with a significant decrease in end diastolic flow velocity in the left pulmonary artery,
infants with a decreased right ventricular systolic pressure, and those with a decreased left atrium aortic
root ratio.5 Upon second treatment with the oral agents paracetamol elicited a greater difference than
ibuprofen in the comparison of pre and post treatment PDA size.5 Dash et al. evaluated the use of
indomethacin and paracetamol, which yielded similar efficacy results as well. Treatment with
paracetamol produced a closure rate of 100% and 94.6% was produced with treatment of ibuprofen.6
There were some slight differences in the adverse effects associated with the use of
paracetamol in comparison to other PDA closing modalities. Within El Mashad et al., substantial kidney
damage was noted within the treatment groups. The patients treated with indomethacin were found to
have the most nephrotoxicity, followed by the patients treated with ibuprofen. The patients treated
with paracetamol were found to have no change in serum creatinine.4 El Farrash et al, reported that
both oral paracetamol and ibuprofen had a similar safety profile. There was no increase in the
occurrence of GI perforation or bleeding, necrotizing enterocolitis, bronchopulmonary dysfunction,
interventricular hemorrhage, thrombocytopenia, hepatic or renal dysfunction with either treatment.5
This was similar to the results yielded by Dash et al. Interestingly, the study found that there was no
increase in adverse effects associated with the use of paracetamol or indomethacin.6 The studies have
depicted that the use of paracetamol in PDA closure is similar in efficacy in comparison to the use of
NSAIDS. However, its use may have an advantage in that it may not be associated with adverse effects,
the most notable of which are the increase in GI bleeds and renal dysfunction.
Conclusion:
Overall, the literature from this meta-analysis supports the use of Paracetamol as treatment for
PDA. Paracetamol has been found to be non-inferior to non-steroidal anti-inflammatories such as
indomethacin and ibuprofen in the closure of PDA. Some research has shown that the use of
paracetamol may decrease the adverse effects associated with NSAID treatment, while others have
shown that there is in fact no difference. Based on this research, there is not enough evidence to
definitively support the decreased adverse effects with Paracetamol versus NSAIDs. It is imperative that
more studies are performed to further demonstrate the increased efficacy and safety of this alternative
approach compared to NSAIDs.
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Appendix
Table 1: Specific inclusion and exclusion criteria for each specific study.
Name of Study

Dash et al.

El-Mashad et al.

El-Farrish et al.

Inclusion and Exclusion Criteria
Inclusion: Weight <1500 grams and echocardiography providing proof of
hs-PDA >1.5mm with a left to right shunt ratio of the left atrium to the
aorta >1.5:1 within the first 48 hours
Exclusion: Patients with any of the following
● Major congenital anomalies
● Sepsis
● platelet count <50,000/mL
● complex congenital heart
● ductal dependent lesions
● inability to administer the drug within 48 hours of birth
● polycystic disease of kidney or multicystic kidney
● maternal tocolytic therapy with prostaglandin inhibitors
● hydrops fetalis
● urine output less than 1mL/kg/hr
Inclusion: Weight <1500 grams or gestational age <28 weeks in the first 2
weeks of life, and a hs-PDA diagnosed with echocardiography
Exclusion: Patients with any of the following
● Major congenital anomalies
● Sepsis
● NEC (Necrotizing Enterocolitis)
● IVH (Intraventricular hemorrhage)
● urine output <1ml/kg/hr in last 24 hours
● elevated creatinine concentration >1.5
● platelet count <100,000/mL
● complex congenital heart
● ductal dependent lesions
Inclusion: Gestational age <34 weeks, postnatal age of 2-7 days, and color
doppler echocardiographic evidence of hs- PDA
Exclusion: Patients with any of the following
● Bleeding tendency
● platelet count <60,000/mm3
● urine output less than 1ml/kg/
● creatinine concentration >1.8 mg/dL
● congenital heart disease
● other major congenital abnormalities

Table 2: Specific statistical tests utilized in each study including study size.
Name of Study

Type of Statistical Tests

P-value Cut off

P value <.05
RR (95% CI)
Dash et al.
α-error= .05
β-error= .2
Power of study=80%
Mean, standard deviation
P value <.05
El-Mashad et
T-test
α-error =.05
al.
ANOVA
Power of study=90%
T-test and ANOVA
P value <.05
El-Farrish et al. Chi-square
α-error =.05
Fisher Exact
Power of study=80%
Hs-PDA: hemodynamically significant patent ductus arteriosus.
Mann Whitney
Fisher exact test
Relative Risk
CI

Study Size

77 preterm neonates
with hs-PDA

300 preterm neonates
with hs-PDA
60 preterm neonates
with hs-PDA

Table 3: Comparison of PDA closure in Paracetamol vs competing anti-prostaglandin agent.
Name of Study

Paracetamol Closures

Other Drug Closures

Dash et al.

36/36

Indomethacin: 35/37

El-Mashad et al.

88/100

Ibuprofen: 83/100
Indomethacin: 88/100

El-Farrash et al.

28/30

24/30

Secondary endpoints are also noted.

Secondary Endpoint
No significant
difference in lab values
or side effects.
Significant increase in
serum creatinine and
BUN. Significant
decrease in platelet
count and urine output
in the ibuprofen and
indomethacin groups,
most severe in
indomethacin.
No significant
difference in lab values
or side effects.

Table 4. Statistical analysis of echocardiographic measurements of Ibuprofen versus Paracetamol
Echocardiographic
Ibuprofen Group
Paracetamol Group
P-value
Finding
LPA
0.35 ± 0.09
0.19 ± 0.06
0.014
RVSP
40.50 ± 12.91
20.50 ± 0.58
0.016
LA/Ao Ratio
1.23 ± 0.14
1.07 ± 0.04
0.046
LPA: end diastolic flow velocity in the left pulmonary artery, m/sec = meter per second. RVSP: right
ventricular systolic pressure, SD = standard deviation. LA/Ao ratio: left atrium to aortic root ratio.

Figure 2: Flow chart showing the comparative drugs and dosages given to the randomized study groups.
Dash et al.

El-Farrash et al.

Randomized 77

Parenteral Paracetamol (38)

Randomized 60

IV Indomethacin (39)

Oral Paracetamol (30)

Oral Ibuprofen (30)

Administration:

Administration:

Administration:

Administration:

Paracetamol drops
through feeding tube
at 15mg/kg/dose, 6
hourly for 7 days

IV indomethacin at
.2mg/kg/dose, once
daily for 3 days

Paracetamol
suspension 250/5mL
at 15mg/kg/6h for 3
days, with second
course given if failure
to close

Ibuprofen suspension
100mg/mL at
10mg/kg/day for first
day, followed by
5mg/kg/day for the
next 2 days. Second
course given for 3
more if still
significant patency

El-Mashad et al.
Randomized 300

Group I: Paracetamol IV (100)

Group II: Ibuprofen IV (100)

Group III: Indomethacin IV (100)

Administration:

Administration:

Administration:

Paracetamol at
15mg/kg IV over 30
minutes, then
15mg/kg/6hrs IV for
3 days

Ibuprofen at
10mg/kg IV followed
by 5mg/kg/day for 2
days

Indomethacin at
.2mg/kg IV over 30
minutes for 3 doses
12 hours apart
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